Marvel Successfully Completes the Dog and Rat GLP Toxicology Studies Required to Enter Human Trials
Calgary, Alberta – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has completed the dosing portion of the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging dog and rat studies for its lead drug candidate MB-204. “We are pleased...
Marvel Commence Final Study Required Prior to Initiating Human Trials
Calgary, Alberta – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging dog studies for its lead drug candidate MB-204. “This dog study is the last of the two...
Marvel Biosciences Initiates Four Week Rat GLP Toxicology Study
Calgary, Alberta – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging rat studies for its lead drug candidate MB-204. “This rat study, along with the GLP study on...
Marvel Biosciences Announces Closing of First Tranche of Debenture Offering
Calgary, Alberta – Marvel Biosciences Corp. ("Marvel" or the "Corporation") announced today that it has completed the closing of the first tranche of the previously announced non-brokered private placement of debentures (“Debentures”) for gross proceeds of $1,000,000 (the “Private Placement”), subject to final approval of the TSX Venture Exchange. The Debentures bear interest at the rate of...
Marvel Biosciences Announces Proposed Debenture Offering
Calgary, Alberta – Marvel Biosciences Corp. ("Marvel" or the "Company") announced today its intention to complete a non-brokered private placement offering of unsecured convertible debentures (“Debentures”) in the principal amount of up to $1,500,000 (the “Private Placement”). The Debentures will bear interest at the rate of eight percent (8%) per annum, payable annually and will mature on the...
Marvel Biosciences Completes a Critical Manufacturing Milestone Required to Enter Phase 1 Human Trials Targeting Alzheimer’s Disease and Depression
Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has successfully completed a multi-kilogram scale run under current good manufacturing practices (“cGMP”) of the active pharmaceutical ingredient (API) of the Company’s lead asset MB-204 in partnership with Zhejiang Ausun...
Marvel Biosciences Successfully Completes its Short Term Dose Ranging Study in Rats and Dogs for MB-204
Marvel Biosciences Corp. (TSV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has successfully completed its dose-ranging toxicology studies in rats and dogs, for its lead drug candidate MB-204. These studies will assist in determining the doses for the IND-enabling 4-week GLP toxicology studies. ...
Marvel Biosciences Announces Letter Agreement For Market Stabilization and Liquidity Services
Marvel Biosciences Inc. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has entered into a Letter Agreement for Market Stabilization and Liquidity Services (the “Consulting Agreement”) with Mr. Adam Smith of Red Cloud Securities Inc. (“Red Cloud”) to support Marvel’s market stabilization and...
Marvel Biosciences Initiates Its Final FDA-Required Experiment Prior to Initiating Human Trials for Its Lead Drug Candidate MB-204
Calgary, Alberta – (December 12, 2022) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), announces it has initiated its 10-day, dose-ranging toxicology study, using dogs, for its lead drug candidate MB-204. To date, the Company’s MB-204 has shown positive and promising data addressing depression,...
Marvel Biosciences Initiates the Next Milestone Study for its Lead Asset MB-204 Targeting Alzheimer’s and Depression
Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has initiated its 7-day dose-ranging, toxicology study, using rats, for its lead molecule MB-204. This is a vital step in preparation to initiate FDA Phase I human clinical trials. “We have significantly de-risked the...